SYGNIS AG

euro adhoc: LION Bioscience AG
Board of Directors (Appointments and Changes)
Management Board Change

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- Cambridge, MA, USA, Heidelberg, Germany, November 17, 2004 - The Supervisory Board of LION bioscience AG has reappointed LION´s Executive Board with immediate effect. Dr. Thure Etzold was appointed Chief Executive Officer (CEO). Peter Willinger, who is head of the finance department since 1998, was appointed Chief Financial Officer (CFO). Joseph F. Donahue moves from the Board and remains responsible for Global Sales and continues to be President of LION bioscience, Inc, LION’s U.S. subsidiary. Peter Willinger joined LION in November 1998 as Director Controlling and served as Vice President Global Finance & Operations since October 2001. After he received his BA degree in business economics at the Mannheim University, he worked as a controller for Rudolf Wild GmbH & Co KG/Heidelberg for eight years. end of announcement euro adhoc 17.11.2004 17:10:37 --------------------------------------------------------------------- Further inquiry note: Günter Dielmann, Tel.: +49 6221 4038-249, guenter.dielmann@lionbioscience.com Julia Fritz, Tel.: +49 6221 4038-158, julia.fritz@lionbioscience.com Branche: Pharmaceuticals ISIN: DE0005043509 WKN: 504350 Index: Nemax 50, Prime Standard, TecDAX Börsen: Frankfurter Wertpapierbörse / regulated dealing New York / regulated dealing Berliner Wertpapierbörse / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade Bremer Wertpapierbörse (BWB) / free trade

Das könnte Sie auch interessieren: